Type I interferon dysregulation and neurological disease

Nature Reviews Neurology

Volumn 11, Issue 9, 2015, Pages 515-523

  McGlasson, Sarah ^a   Jury, Alexa ^a   Jackson, Andrew ^a   Hunt, David ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; JANUS KINASE INHIBITOR;

AUTOIMMUNE DISEASE; BRAIN DISEASE; CEREBROVASCULAR DISEASE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; GENE MUTATION; GENETIC VARIABILITY; HERPES SIMPLEX ENCEPHALITIS; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; INFECTION SENSITIVITY; INFLAMMATORY DISEASE; INNATE IMMUNITY; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS INFECTION; ANIMAL; BRAIN; IMMUNOLOGY; METABOLISM; NERVOUS SYSTEM DISEASES;

ANIMALS; BRAIN; HUMANS; INTERFERON TYPE I; NERVOUS SYSTEM DISEASES;

EID: 84941022179     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.143     Document Type: Review

References (119)

1. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258-267 (1957
2. Isaacs, A., Lindenmann, J. & Valentine, R. C. Virus interference. II. Some properties of interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 268-273 (1957
3. Nagano, Y., Kojima, Y. & Sawai, Y. Immunity and interference in vaccinia; inhibition of skin infection by inactivated virus [French]. C. R. Seances Soc. Biol. Fil. 148, 750-752 (1954
4. Wheelock, E. F. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 149, 310-311 (1965
5. Field, A. K., Tytell, A. A., Lampson, G. P. & Hilleman, M. R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl Acad. Sci. USA 58, 1004-1010 (1967
6. Crow, Y. J. Type I interferonopathies: A novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 1238, 91-98 (2011
7. Olopade, O. I. et al. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 14, 437-443 (1992
8. Altmann, S. M., Mellon, M. T., Distel, D. L. & Kim, C. H. Molecular and functional analysis of an interferon gene from the zebrafish, Danio rerio. J. Virol. 77, 1992-2002 (2003
9. Robertsen, B., Bergan, V., Rokenes, T., Larsen, R. & Albuquerque, A. Atlantic salmon interferon genes: cloning, sequence analysis, expression, and biological activity. J. Interferon Cytokine Res. 23, 601-612 (2003
10. Xu, L., Yang, L. & Liu, W. Distinct evolution process among type I interferon in mammals. Protein Cell 4, 383-392 (2013
11. Kerkmann, M. et al. Activation with CpG A and CpG B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170, 4465-4474 (2003
12. Takauji, R. et al. CpG DNA induced IFN a production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. J. Leukoc. Biol. 72, 1011-1019 (2002
13. Izaguirre, A. et al. Comparative analysis of IRF and IFN-Alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74, 1125-1138 (2003
14. Desmet, C. J. & Ishii, K. J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat. Rev. Immunol. 12, 479-491 (2012
15. Oldenburg, M. et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 337, 1111-1115 (2012
16. Rigby, R. E. et al. RNA:DNA hybrids are a novel molecular pattern sensed by TLR9. EMBO J. 33, 542-558 (2014
17. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010
18. Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674-678 (2008
19. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788-792 (2009
20. De Weerd, N. A., Samarajiwa, S. A. & Hertzog, P. J. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282, 20053-20057 (2007
21. Van Boxel-Dezaire, A. H., Rani, M. R. & Stark, G. R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25, 361-372 (2006
22. Schoggins, J. W. & Rice, C. M. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1, 519-525 (2011
23. Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485 (2011
24. Ma, F. et al. Positive feedback regulation of type I interferon by the interferon-stimulated gene STING. EMBO Rep. 16, 202-212 (2015
25. Kim, M. J., Hwang, S. Y., Imaizumi, T. & Yoo, J. Y. Negative feedback regulation of RIG I mediated antiviral signaling by interferon-induced ISG15 conjugation. J. Virol. 82, 1474-1483 (2008
26. Staeheli, P., Pitossi, F. & Pavlovic, J. Mx proteins: GTPases with antiviral activity. Trends Cell Biol. 3, 268-272 (1993
27. Zurcher, T., Pavlovic, J. & Staeheli, P. Mechanism of human MxA protein action: variants with changed antiviral properties. EMBO J. 11, 1657-1661 (1992
28. Haller, O. & Kochs, G. Human MxA protein: An interferon-induced dynamin-like GTPase with broad antiviral activity. J. Interferon Cytokine Res. 31, 79-87 (2011
29. Kochs, G., Janzen, C., Hohenberg, H. & Haller, O. Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes. Proc. Natl Acad. Sci. USA 99, 3153-3158 (2002
30. Kochs, G., Haener, M., Aebi, U. & Haller, O. Self-Assembly of human MxA GTPase into highly ordered dynamin-like oligomers. J. Biol. Chem. 277, 14172-14176 (2002
31. Reichelt, M., Stertz, S., Krijnse-Locker, J., Haller, O. & Kochs, G. Missorting of LaCrosse virus nucleocapsid protein by the interferon-induced MxA GTPase involves smooth ER membranes. Traffic 5, 772-784 (2004
32. Samarajiwa, S. A., Forster, S., Auchettl, K. & Hertzog, P. J. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 37, D852-D857 (2009
33. Lafaille, F. G. et al. Impaired intrinsic immunity to HSV 1 in human iPSC-derived TLR3-deficient CNS cells. Nature 491, 769-773 (2012
34. Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921 (1994
35. Detje, C. N. et al. Local type I IFN receptor signaling protects against virus spread within the central nervous system. J. Immunol. 182, 2297-2304 (2009
36. Detje, C. N. et al. Upon intranasal vesicular stomatitis virus infection, astrocytes in the olfactory bulb are important interferon Beta producers that protect from lethal encephalitis. J. Virol. 89, 2731-2738 (2015
37. Campbell, I L. et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN a. Brain Res. 835, 46-61 (1999
38. Akwa, Y. et al. Transgenic expression of IFN a in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J. Immunol. 161, 5016-5026 (1998
39. Granerod, J. et al. Causes of encephalitis and differences in their clinical presentations in England: A multicentre, population-based prospective study. Lancet Infect. Dis. 10, 835-844 (2010
40. Smith, M. G., Lennette, E. H. & Reames, H. R. Isolation of the virus of herpes simplex and the demonstration of intranuclear inclusions in a case of acute encephalitis. Am. J. Pathol. 17, 55-681 (1941
41. Whitley, R. J. Herpes simplex virus in children. Curr. Treat. Options Neurol. 4, 231-237 (2002
42. Najioullah, F. et al. Diagnosis and surveillance of herpes simplex virus infection of the central nervous system. J. Med. Virol. 61, 468-473 (2000
43. Nahmias, A. J., Lee, F. K. & Beckman-Nahmias, S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis. Suppl. 69, 19-36 (1990
44. Lerner, A. M., Levine, D. P. & Reyes, M. P. Two cases of herpes simplex virus encephalitis in the same family. N. Engl. J. Med. 308, 1481 (1983
45. Jackson, A. C., Melanson, M. & Rossiter, J. P. Familial herpes simplex encephalitis. Ann. Neurol. 51, 406-407 (2002
46. Koskiniemi, M. et al. Familial herpes encephalitis. Lancet 346, 1553 (1995
47. Abel, L. et al. Age-dependent Mendelian predisposition to herpes simplex virus type 1 encephalitis in childhood. J. Pediatr. 157, 623-629, 629.e1 (2010
48. Dupuis, S. et al. Impaired response to interferon a/β and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33, 388-391 (2003
49. Kong, X. F. et al. A novel form of human STAT1 deficiency impairing early but not late responses to interferons. Blood 116, 5895-5906 (2010
50. Casrouge, A. et al. Herpes simplex virus encephalitis in human UNC 93B deficiency. Science 314, 308-312 (2006
51. Kim, Y. M., Brinkmann, M. M., Paquet, M. E. & Ploegh, H. L. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 452, 234-238 (2008
52. Zhang, S. Y. et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317, 1522-1527 (2007
53. Guo, Y. et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 208, 2083-2098 (2011
54. Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin 1 receptor antagonist. N. Engl. J. Med. 360, 2426-2437 (2009
55. Aicardi, J. & Goutières, F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann. Neurol. 15, 49-54 (1984
56. Lebon, P. et al. Intrathecal synthesis of interferon-Alpha in infants with progressive familial encephalopathy. J. Neurol. Sci. 84, 201-208 (1988
57. Rice, G. I. et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: A case-control study. Lancet Neurol. 12, 1159-1169 (2013
58. Crow, Y. J. et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat. Genet. 38, 917-920 (2006
59. Crow, Y. J. et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat. Genet. 38, 910-916 (2006
60. Rice, G. I. et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 41, 829-832 (2009
61. Goldstone, D. C. et al. HIV 1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480, 379-382 (2011
62. Alarcon-Riquelme, M. E. Nucleic acid by-products and chronic inflammation. Nat. Genet. 38, 866-867 (2006
63. Rigby, R. E., Leitch, A. & Jackson, A. P. Nucleic acid-mediated inflammatory diseases. Bioessays 30, 833-8 (2008
64. Yang, Y. G., Lindahl, T. & Barnes, D. E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131, 873-886 (2007
65. Rice, G. I. et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat. Genet. 44, 1243-1248 (2012
66. Livingston, J. H. et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J. Med. Genet. 51, 76-82 (2014
67. Mannion, N. M. et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 9, 1482-1494 (2014
68. Rice, G. I. et al. Gain of function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet. 46, 503-509 (2014
69. Rice, G. et al. Clinical and molecular phenotype of Aicardi-Goutières syndrome. Am. J. Hum. Genet. 81, 713-725 (2007
70. Ramesh, V. et al. Intracerebral large artery disease in Aicardi-Goutières syndrome implicates SAMHD1 in vascular homeostasis. Dev. Med. Child Neurol. 52, 725-732 (2010
71. Crow, Y. J. et al. Cree encephalitis is allelic with Aicardi-Goutières syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J. Med. Genet. 40, 183-187 (2003
72. Zhang, X. et al. Human intracellular ISG15 prevents interferon a/β over-Amplification and auto-inflammation. Nature 517, 89-93 (2015
73. Livingston, J. H., Stivaros, S., Van Der Knaap, M. S. & Crow, Y. J. Recognizable phenotypes associated with intracranial calcification. Dev. Med. Child Neurol. 55, 46-57 (2013
74. Goldmann, T. et al. USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J. 34, 1612-1629 (2015
75. Rice, G. et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutières syndrome. Am. J. Hum. Genet. 80, 811-815 (2007
76. Navarro, V. et al. Two further cases of spondyloenchondrodysplasia (SPENCD) with immune dysregulation. Am. J. Med. Genet. A 146A, 2810-2815 (2008
77. Briggs, T. A. et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 43, 127-131 (2011
78. Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371, 507-518 (2014
79. Lisnevskaia, L., Murphy, G. & Isenberg, D. Systemic lupus erythematosus. Lancet 384, 1878-1888 (2014
80. Botto, M. et al. Complement in human diseases: Lessons from complement deficiencies. Mol. Immunol. 46, 2774-2783 (2009
81. Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383-392 (2006
82. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003
83. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003
84. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN) et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204-210 (2008
85. Gateva, V. et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41, 1228-1233 (2009
86. Dale, R. C., Tang, S. P., Heckmatt, J. Z. & Tatnall, F. M. Familial systemic lupus erythematosus and congenital infection-like syndrome. Neuropediatrics 31, 155-158 (2000
87. De Laet, C. et al. Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutières syndrome. Neuropediatrics 36, 399-402 (2005
88. Lee-Kirsch, M. A. et al. A mutation in TREX1 that impairs susceptibility to granzyme A mediated cell death underlies familial chilblain lupus. J. Mol. Med. (Berl.) 85, 531-537 (2007
89. Lee-Kirsch, M. A. et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39, 1065-1067 (2007
90. Namjou, B. et al. Evaluation of the TREX1 gene in a large multi-Ancestral lupus cohort. Genes Immun. 12, 270-279 (2011
91. De Vries, B. et al. TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Ann. Rheum. Dis. 69, 1886-1887 (2010
92. Günther, C. et al. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J. Clin. Invest. 125, 413-424 (2015
93. Reijns, M. A. et al. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell 149, 1008-1022 (2012
94. Tan, F. K. et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45, 694-702 (2006
95. Barth, P. G., Walter, A. & Van Gelderen, I. Aicardi-Goutières syndrome: A genetic microangiopathy?. Acta Neuropathol. 98, 212-216 (1999
96. Rasmussen, M., Skullerud, K., Bakke, S. J., Lebon, P. & Jahnsen, F. L. Cerebral thrombotic microangiopathy and antiphospholipid antibodies in Aicardi-Goutières syndrome-report of two sisters. Neuropediatrics 36, 40-44 (2005
97. Hanly, J. G., Walsh, N. M. & Sangalang, V. Brain pathology in systemic lupus erythematosus. J. Rheumatol. 19, 732-741 (1992
98. Richards, A. et al. C terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet. 39, 1068-1070 (2007
99. Kolar, G. R. et al. Neuropathology and genetics of cerebroretinal vasculopathies. Brain Pathol. 24, 510-518 (2014
100. Mateen, F. J. et al. Evolution of a tumor-like lesion in cerebroretinal vasculopathy and TREX1 mutation. Neurology 75, 1211-1213 (2010
101. Schuh, E. et al. Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL. Neurol. Neuroimmunol. Neuroinflamm. 2, e55 (2015
102. Pelzer, N. et al. Heterozygous TREX1 mutations in early-onset cerebrovascular disease. J. Neurol. 260, 2188-2190 (2013
103. Magee, C. C. Renal thrombotic microangiopathy induced by interferon-Alpha. Nephrol. Dial. Transplant. 16, 2111-2112 (2001
104. Larochelle, C. et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β. Mult. Scler. 20, 1783-1787 (2014
105. Hunt, D. et al. Thrombotic microangiopathy associated with interferon beta. N. Engl. J. Med. 370, 1270-1271 (2014
106. Magro, C. M. et al. Degos disease: A C5b 9/interferon a-mediated endotheliopathy syndrome. Am. J. Clin. Pathol. 135, 599-610 (2011
107. Crow, Y. J. & Manel, N. Aicardi-Goutières syndrome and the type I interferonopathies. Nat. Rev. Immunol. 15, 429-440 (2015
108. Cuadrado, E. et al. Phenotypic variation in Aicardi-Goutières syndrome explained by cell-specific IFN-stimulated gene response and cytokine release. J. Immunol. 194, 3623-3633 (2015
109. Van Heteren, J. T. et al. Astrocytes produce interferon-Alpha and CXCL10, but not IL 6 or CXCL8, in Aicardi-Goutières syndrome. Glia 56, 568-578 (2008
110. Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134, 587-598 (2008
111. Gall, A. et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36, 120-131 (2012
112. Morita, M. et al. Gene-targeted mice lacking the Trex1 (DNase III) 3'5' DNA exonuclease develop inflammatory myocarditis. Mol. Cell. Biol. 24, 6719-6727 (2004
113. Beck-Engeser, G. B., Eilat, D. & Wabl, M. An autoimmune disease prevented by anti-retroviral drugs. Retrovirology 8, 91 (2011
114. Volkman, H. E. & Stetson, D. B. The enemy within: endogenous retroelements and autoimmune disease. Nat. Immunol. 15, 415-422 (2014
115. Petri, M. et al. Sifalimumab, a human anti interferon a monoclonal antibody, in systemic lupus erythematosus: A phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 65, 1011-1021 (2013
116. Merrill, J. T. et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70, 1905-1913 (2011
117. Crow, Y. J. et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am. J. Med. Genet. A 167A, 296-312 (2015
118. Polman, C. H. et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 9, 740-750 (2010
119. Klippel, J. H., Carette, S., Preble, O. T., Friedman, R. M. & Grimley, P. M. Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus. Ann. Rheum. Dis. 44, 104-108 (1985